Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Pfizer is the sole supplier of vincristine, while Teva makes a branded version of the medicine known as Vincasar....
...Other large drugmakers, including Allergan, GlaxoSmithKline, Gilead, Shire, Biogen, Teva, Baxter and Viiv also increased the US list prices of their medicines on January 1, according to the data....
...Last year, Baxter revealed it had been subpoenaed by the DoJ as part of its investigation, while Pfizer and ICU Medical, the former and current owners of Hospira Infusion, respectively, also received subpoenas...
...J&J’s condemnation follows several similar interventions by drugmakers such as Pfizer, Roche and Baxter....
...Mr Read also sought to distance Pfizer from other companies that have been broken up in recent years, such as Abbott Laboratories, which spun out its branded drugs business as AbbVie, and Baxter Health,...
...Meanwhile, Abbott and Baxter, two diversified US healthcare groups, spun off AbbVie and Baxalta, respectively, as standalone pharma companies....
...Other biotech companies, such as Alexion and BioMarin, have made a name for themselves in the field and big manufacturers including Sanofi, GlaxoSmithKline and Pfizer have made heavy commitments....
...Pfizer, which is also under pressure from investors over sluggish growth, announced its own deal on Wednesday with a $635m agreement to buy a portfolio of vaccines from Baxter International, a rival US drugmaker...
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Sales at its main Baxter Storey contract catering brand, which accounts for 65 per cent of sales, grew 11.1 per cent to £311.5m....
..., Baxter, BMS, Eli Lilly, AstraZeneca and Smith & Nephew....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Deal activity and changes at the top of Pfizer and Kellogg failed to stop US stocks following global markets slightly lower....
...A host of big pharmaceutical companies – Merck, AstraZeneca, Eli Lilly, Baxter, SciClone, and Bristol-Myers Squibb – have in recent months received inquiries from the Department of Justice and the Securities...
...Merck, AstraZeneca, Eli Lilly, Baxter, SciClone, and Bristol-Myers Squibb have in recent months received inquiries from the DoJ and the Securities and Exchange Commission in connection with an industry-wide...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...ever Blu-ray 3D disc – a copy of Dreamworks’ Monsters v Aliens....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Yet Pfizer’s $68bn acquisition of Wyeth and Merck’s $41bn bid for Schering-Plough will only affect research pipelines at the margins....
...Bard and Baxter, the two medical device groups, the consumer group P&G and cigarette company Altria are other suggestions....
International Edition